| Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer Y Zheng, Z Wang, S Wei, Z Liu, G Chen Cancer letters 499, 148-163, 2021 | 57 | 2021 |
| Wi-fi provisioning techniques DJ Hutz, C Silverman, BA Berg, Y Zheng US Patent 10,419,908, 2019 | 13 | 2019 |
| Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer Y Zheng, L Tang, Z Liu BMC cancer 21 (1), 1322, 2021 | 9 | 2021 |
| Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity S Dou, G Li, G Li, C Hou, Y Zheng, L Tang, Y Gao, R Mo, Y Li, R Wang, ... Elife 10, e66501, 2021 | 9 | 2021 |
| Tim-3 relieves experimental autoimmune encephalomyelitis by suppressing MHC-II L Tang, G Li, Y Zheng, C Hou, Y Gao, Y Hao, Z Gao, R Mo, Y Li, B Shen, ... Frontiers in Immunology 12, 770402, 2022 | 8 | 2022 |
| Comprehensive bioinformatics analysis of key methyltransferases and demethylases for histone lysines in hepatocellular carcinoma Y Zheng, L Tang, G Chen, Z Liu Technology in Cancer Research & Treatment 19, 1533033820983284, 2020 | 8 | 2020 |
| Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve C Li, Y Qiao, X Jiang, L Liu, Y Zheng, Y Qiu, C Cheng, F Zhou, Y Zhou, ... Journal of Medicinal Chemistry 66 (17), 12432-12445, 2023 | 4 | 2023 |
| Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection Y Qiao, JW Wotring, CJ Zhang, X Jiang, L Xiao, A Watt, D Gattis, ... PloS one 18 (2), e0281281, 2023 | 4 | 2023 |
| Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy Y Bao, Y Qiao, JE Choi, Y Zhang, R Mannan, C Cheng, T He, Y Zheng, ... Proceedings of the National Academy of Sciences 120 (49), e2314416120, 2023 | 3 | 2023 |
| p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer J Luo, Z Chen, Y Qiao, JCY Tien, E Young, R Mannan, S Mahapatra, T He, ... bioRxiv, 2024 | 1 | 2024 |
| Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies T He, L Xiao, Y Qiao, O Klingbeil, E Young, XS Wu, R Mannan, ... bioRxiv, 2024.01. 22.576669, 2024 | 1 | 2024 |
| Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response Y Qiao, JW Wotring, Y Zheng, CJ Zhang, Y Zhang, X Jiang, CD Pretto, ... Proceedings of the National Academy of Sciences 120 (30), e2221809120, 2023 | 1 | 2023 |
| Wi-Fi provisioning techniques DJ Hutz, C Silverman, BA Berg, Y Zheng US Patent 11,510,038, 2022 | 1 | 2022 |
| Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer T He, C Cheng, Y Qiao, H Cho, E Young, R Mannan, S Mahapatra, ... Proceedings of the National Academy of Sciences 121 (15), e2322563121, 2024 | | 2024 |
| Harnessing PIKfyve as a therapeutic vulnerability in neuroendocrine prostate cancer Y Zheng, KG Rogers, AG Kamat, SN Yee, R Mannan, X Jiang, ... Cancer Research 84 (6_Supplement), 3299-3299, 2024 | | 2024 |
| Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy P Borker, Y Bao, Y Qiao, A Chinnaiyan, JE Choi, Y Zhang, R Mannan, ... Cancer Research 84 (6_Supplement), 7479-7479, 2024 | | 2024 |
| Development of the lipid kinase PIKfyve PROTAC degrader against neuroendocrine prostate cancer Y Qiao, C Li, Y Zheng, X Jiang, SN Yee, C Cheng, Y Bao, Y Zhang, ... Cancer Research 84 (6_Supplement), 2898-2898, 2024 | | 2024 |
| Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer C Cheng, J Hu, R Mannan, R Bhattacharyya, NJ Rossiter, B Magnuson, ... bioRxiv, 2024.03. 18.585580, 2024 | | 2024 |
| PIKfyve controls dendritic cell function and tumor immunity JE Choi, Y Qiao, I Kryczek, J Yu, J Gurkan, Y Bao, M Gondal, JCY Tien, ... bioRxiv, 2024.02. 28.582543, 2024 | | 2024 |
| Suggested searches JCV Stacey, A Tan, JM Lu, LC James, JAG Briggs, Z Dulberg, R Dubey, ... Perspective, 2023 | | 2023 |
